摘要
目的研究晚期结直肠癌患者化疗联合贝伐珠单抗治疗的临床效果及安全性。方法 60例晚期结直肠癌患者,给予化疗方案XELOX、mFOLFOX6或FOLFIRI,化疗期间联合贝伐珠单抗治疗。观察患者的临床疗效和不良反应发生情况。结果 60例结直肠癌患者中,完全缓解9例(15.00%),部分缓解19例(31.67%),稳定16例(26.67%),进展16例(26.67%),治疗总有效率为46.67%,疾病控制率为73.33%。不良反应发生情况:蛋白尿5例(8.33%),皮疹5例(8.33%),高血压3例(5.00%),便血4例(6.67%),不良反应发生率为28.33%。结论对晚期结直肠癌患者在化疗治疗中联合贝伐珠单抗的疗效显著,具有一定的安全性,可有效缓解患者治疗期间的临床症状,改善患者的生活质量,值得临床推广使用。
Objective To study the clinical effect and safety of bevacizumab combined with chemotherapy in advanced colorectal cancer. Methods A total of 60 patients with advanced colorectal cancer received chemotherapy regimen of XELOX, mFOLFOX6 or FOLFIRI, combined with bevacizumab during chemotherapy. The clinical efficacy and occurrence of adverse reactions in all patients were observed. Results Of the 60 patients with colorectal cancer, there were 9 cases(15.00%) of complete remission, 19 cases(31.67%) of partial remission, 16 cases(26.67%) of stable remission, 16 cases(26.67%) of progress, with total treatment effective rate as 46.67%, and the disease control rate as 73.33%. Adverse reactions: proteinuria in 5 cases(8.33%), rash in 5 cases(8.33%), hypertension in 3 cases(5.00%), stool blood in 4 cases(6.67%), with incidence of adverse reactions as 28.33%. Conclusion The combination of bevacizumab and chemotherapy is effective and safe for advanced colorectal cancer patients. It can alleviate the clinical symptoms during the treatment and improve the quality of life of patients. It can be widely promoted and used in the clinical.
作者
邓权通
许瑞莲
郑涛
曹华
朱美琴
DENG Quan-tong;XU Rui-lian;ZHENG Tao(Department of Internal Medicine-Oncology, Shenzhen People's Hospital,Shenzhen 518020,China)
出处
《中国实用医药》
2018年第36期109-110,共2页
China Practical Medicine
基金
20150063贝伐珠单抗耐药大肠癌的新药物靶点肿瘤标记物的研究(项目编号:JCYJ20150901153557178)
关键词
晚期结直肠癌
贝伐珠单抗
化疗
安全性
Advanced colorectal cancer
Bevacizumab
Chemotherapy
Safety
